AAPLLoadingMSFTLoadingNVDALoadingGOOGLLoadingAMZNLoadingMETALoadingTSLALoadingAMDLoadingNFLXLoadingCOINLoadingPYPLLoadingSPYLoadingQQQLoadingIWMLoadingJPMLoadingVLoadingDISLoadingKOLoadingJNJLoadingNKELoadingXOMLoadingASMLLoading
FreeVRTX3 min read

A franchise drug is a countdown, and everyone can read the clock

It traded at 502.36 this morning, -0.52% on the session. When a company earns most of its profit from a small number of protected products, the investment case is a race against a date that is already known.

VRTX
Delayed

The structure of the problem

A successful drug earns extraordinary margins while protected. On expiry, generic competition arrives and the revenue does not decline gradually, it falls off. The date is public. The size of the cliff is calculable. None of this is a surprise to anyone.

Which means the entire question is whether the pipeline replaces the revenue before the clock runs out, and by how much.

Why it still gets mispriced

Because the pipeline's value depends on outcomes nobody knows, while the cliff's cost is arithmetic. Analysts are more comfortable with arithmetic, so the cliff tends to be modelled precisely and the replacement modelled with a wave of the hand in either direction.

  • Revenue concentration in the protected products, and the expiry schedule
  • Late-stage programmes, their addressable populations and their realistic timelines
  • Whether the pipeline addresses the same disease area, where the commercial infrastructure already exists
  • Cash position, since replacement can be bought as well as developed

That last one is often the real answer. A company facing a cliff with a large cash balance has an option the pipeline slides do not show.

Why I am flat

I can price the cliff exactly. I cannot price the replacement at all. Averaging a precise number with a guess produces a guess.

What would resolve it

Late-stage data. Not a partial readout, not a subgroup, not an interim. The full result on a programme large enough to matter against the cliff.

Until that lands this is a position I would be taking on hope, and hope belongs in a basket rather than a concentrated holding.

The author holds no position in the instruments discussed. Opinion. Not advice. Not a financial promotion approved under FSMA s.21. Quote data is delayed. Past performance is not a reliable indicator of future results.

Comments

0 comments
Sign in to comment.

No comments yet

Be the first to weigh in.